A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To evaluate the safety and efficacy of diclazuril capsules as a treatment for cryptosporidial related diarrhea in AIDS patients who have been treated in the double-blind study # JRD 64,433/1101 and have relapsed, or de-novo patients who have been diagnosed with cryptosporidial related diarrhea and who meet the inclusion and exclusion criteria of this protocol.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
12 Years to 65 Years (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Didanosine (ddI) allowed but discouraged, must have been stabilized on a constant dose for 3 weeks or more.
Nystatin for control of oropharyngeal infections. Nystatin must not be taken within two hours of diclazuril.
Ganciclovir therapy only for CMV retinitis is permitted if the patient has been treated for at least 4 weeks prior to study entry and is stable on the drug.
Loperamide may be taken if patient has been on long term loperamide prior to study entry but should not be started during the course of this protocol.
Patients must have the following:
Written informed consent given after the purpose and nature of the study, as well as the possible adverse effects related to the study drug, have been explained.
Be willing and able to return for all subsequent weekly visits and the two week visit post completion of therapy (follow-up).
Patients with the following conditions or symptoms are excluded:
Estimated survival less than 28 days.
Other treatable enteric pathogens must be treated and eradicated prior to study entry.
Other antibiotics or antiprotozoal drugs.
Other investigational agents.
Antifungal medications except nystatin.
Ganciclovir for other than Cytomegalovirus (CMV) retinitis.
Antidiarrheal agents other than patients on long term loperamide prior to study entry.
Patients with the following are excluded:
Undependable in following the instructions of the investigator.